PL2722052T3 - Sposoby osłabienia uwalniania zapalnych mediatorów i peptydów użyteczne w niniejszym zgłoszeniu - Google Patents

Sposoby osłabienia uwalniania zapalnych mediatorów i peptydów użyteczne w niniejszym zgłoszeniu

Info

Publication number: PL2722052T3
Authority: PL; Poland
Prior art keywords: methods; inflammatory mediators; peptides useful; attenuating; release
Prior art date: 2006-07-26

Application number

PL14151431T

Other languages

English (en)

Inventor

Indu Parikh

Original Assignee

Biomarck Pharmaceuticals, Ltd.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-07-26

Filing date

2007-07-26

Publication date

2019-08-30

2007-07-26 Application filed by Biomarck Pharmaceuticals, Ltd. filed Critical Biomarck Pharmaceuticals, Ltd.

2019-08-30 Publication of PL2722052T3 publication Critical patent/PL2722052T3/pl

Links

230000002757 inflammatory effect Effects 0.000 title 1
102000004196 processed proteins & peptides Human genes 0.000 title 1
108090000765 processed proteins & peptides Proteins 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Zoology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Neurosurgery (AREA)
Otolaryngology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Transplantation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)

PL14151431T 2006-07-26 2007-07-26 Sposoby osłabienia uwalniania zapalnych mediatorów i peptydów użyteczne w niniejszym zgłoszeniu PL2722052T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US83323906P	2006-07-26	2006-07-26
EP14151431.5A EP2722052B1 (en)	2006-07-26	2007-07-26	Methods For Attenuating Release Of Inflammatory Mediators And Peptides Useful Therein
PCT/US2007/074514 WO2008014414A2 (en)	2006-07-26	2007-07-26	Methods for attenuating release of inflammatory mediators and peptides useful therein
EP07840538.8A EP2053915B1 (en)	2006-07-26	2007-07-26	Peptides for attenuating release of inflammatory mediators

Publications (1)

Publication Number	Publication Date
PL2722052T3 true PL2722052T3 (pl)	2019-08-30

Family

ID=38982357

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL14151431T PL2722052T3 (pl)	2006-07-26	2007-07-26	Sposoby osłabienia uwalniania zapalnych mediatorów i peptydów użyteczne w niniejszym zgłoszeniu
PL07840538T PL2053915T3 (pl)	2006-07-26	2007-07-26	Peptydy służące do łagodzenia uwalniania mediatorów zapalenia

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL07840538T PL2053915T3 (pl)	2006-07-26	2007-07-26	Peptydy służące do łagodzenia uwalniania mediatorów zapalenia

Country Status (21)

Country	Link
US (6)	US8999915B2 (pl)
EP (2)	EP2722052B1 (pl)
JP (2)	JP5378998B2 (pl)
KR (1)	KR101599894B1 (pl)
CN (2)	CN103990111B (pl)
AU (1)	AU2007279193B2 (pl)
BR (1)	BRPI0714953A2 (pl)
CA (2)	CA2658949C (pl)
DK (2)	DK2053915T3 (pl)
ES (2)	ES2725599T3 (pl)
HR (1)	HRP20140587T1 (pl)
IL (1)	IL196667A (pl)
MX (1)	MX2009000975A (pl)
NO (1)	NO20090304L (pl)
PL (2)	PL2722052T3 (pl)
PT (1)	PT2053915E (pl)
RU (1)	RU2423376C2 (pl)
SG (2)	SG10201500418QA (pl)
SI (1)	SI2053915T1 (pl)
WO (1)	WO2008014414A2 (pl)
ZA (1)	ZA200900550B (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2006078899A2 (en)	2005-01-20	2006-07-27	Biomarck Pharmaceuticals, Ltd.	Mucin hypersecretion inhibitors based on the structure of mans and methods of use
SG10201500418QA (en)	2006-07-26	2015-03-30	Biomarck Pharmaceuticals Ltd	Methods for attenuating release of inflammatory mediators and peptides useful therein
ES2509616T3 (es) *	2009-06-25	2014-10-17	Nestec S.A.	Procedimientos de diagnóstico del síndrome del intestino irritable
WO2011060349A1 (en) *	2009-11-13	2011-05-19	North Carolina State University	Methods of modulating mesenchymal stem cells
CN105517562B (zh)	2013-04-05	2018-12-28	拜欧马可医药公司	转移抑制剂
WO2015013669A1 (en)	2013-07-26	2015-01-29	The Regents Of The University Of California	Mps peptides and use thereof
US10314889B2 (en)	2013-12-20	2019-06-11	The Regents Of The University Of California	Suppression of allergic lung inflammation and hyperreactivity
KR102181548B1 (ko) *	2019-02-20	2020-11-20	한국외국어대학교 연구산학협력단	염증성 질환 또는 자가면역성 질환의 예방 또는 치료 활성을 갖는 펩타이드 및 이의 용도
KR20210151945A (ko)	2019-04-12	2021-12-14	립타이드 바이오사이언스, 인코포레이티드	대식세포 활성을 조정하기 위한 방법
CN114302706A (zh)	2019-06-17	2022-04-08	碧奥马尔克制药有限公司	治疗葡萄膜炎的肽及其使用方法
EP4475866A4 (en) *	2022-02-07	2026-02-25	Park Strategic Ventures Llc	Peptides and their methods of use in the treatment of eye disorders
CA3250538A1 (en) *	2022-04-25	2023-11-02	Park Strategic Venture Group, LLC	PEPTIDES AND RELATED METHODS OF USE IN THE TREATMENT OF SKIN DISEASES
CN116375796B (zh) *	2022-11-24	2026-05-26	华南农业大学	一种来源于珍珠贝的抗炎肽及其应用
WO2025123114A1 (pt)	2023-12-15	2025-06-19	Chemyunion Ltda	Composição cosmética, cosmecêutica e/ou farmacêutica, usos e métodos

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS61265341A (ja) *	1985-05-17	1986-11-25	Kawasaki Heavy Ind Ltd	Ｖ型エンジンのシリンダ−ブロツク構造
US4873346A (en)	1985-09-20	1989-10-10	The Upjohn Company	Substituted benzothiazoles, benzimidazoles, and benzoxazoles
US4753945A (en)	1986-02-19	1988-06-28	Eye Research Institute Of Retina Foundation	Stimulation of tear secretion with phosphodiesterase inhibitors
US4966848A (en) *	1988-02-08	1990-10-30	The General Hospital Corporation	Isolation, purification, characterization, cloning and sequencing of N α-acetyltransferase
CA2003316A1 (en)	1988-11-18	1990-05-18	John F. Oram	Hdl-binding proteins
US5223421A (en) *	1989-10-25	1993-06-29	The General Hospital Corporation	Identification of methionine Nα-acetyltransferase
WO1992005784A1 (en)	1990-10-02	1992-04-16	Warner-Lambert Company	4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine derivatives and analogues as angiotensin ii receptor antagonists
US5292498A (en)	1991-06-19	1994-03-08	The University Of North Carolina At Chapel Hill	Method of treating lung disease with uridine triphosphates
WO1993000353A1 (en)	1991-06-20	1993-01-07	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Sequences characteristic of human gene transcription product
US5858784A (en)	1991-12-17	1999-01-12	The Regents Of The University Of California	Expression of cloned genes in the lung by aerosol- and liposome-based delivery
EP0551200A1 (en)	1992-01-07	1993-07-14	National University Of Singapore	Protein phosphatase inhibitors for use in therapy
US5298506A (en)	1992-05-08	1994-03-29	Brigham And Women's Hospital	Use of guanylate cyclase inhibitors in the treatment of shock
US5861502A (en)	1992-11-09	1999-01-19	Thomas Jefferson University	Antisense oligonucleotides to inhibit expression of mutated and wild type genes for collagen
US5512269A (en)	1993-06-09	1996-04-30	Burroughs Wellcome, Co.	Method of treating retained pulmonary secretions
US5849719A (en)	1993-08-26	1998-12-15	The Regents Of The University Of California	Method for treating allergic lung disease
US5858981A (en)	1993-09-30	1999-01-12	University Of Pennsylvania	Method of inhibiting phagocytosis
US5436243A (en)	1993-11-17	1995-07-25	Research Triangle Institute Duke University	Aminoanthraquinone derivatives to combat multidrug resistance
CA2187322A1 (en)	1994-04-07	1995-10-19	Israel Rubinstein	Vasoactive intestinal polypeptide
US5985822A (en)	1994-12-09	1999-11-16	The Scripps Research Institute	Inhibition of glial cell proliferation with N-CAM homophilic peptides
US6713605B1 (en)	1996-04-10	2004-03-30	Kansas State University Research Foundation	Synthetic peptides that inhibit leukocyte superoxide anion production and/or attract leukocytes
US5688489A (en) *	1995-09-15	1997-11-18	Resolution Pharmaceuticals, Inc.	Non-receptor mediated imaging agents
GB9620390D0 (en)	1996-09-30	1996-11-13	Eisai London Res Lab Ltd	Substances and their uses
DE19716713A1 (de)	1997-04-21	1998-10-22	Paz Arzneimittelentwicklung	Arzneimittel, enthaltend Ibuprofenthioester als Hemmer der Nf-kappaB abhängigen Bildung von Mediatoren von Entzündung und Schmerz
ATE553121T1 (de)	1999-02-24	2012-04-15	Univ North Carolina State	Verbindungen zur veränderung der schleimsekretion
US8501911B2 (en)	1999-02-24	2013-08-06	Biomarck Pharmaceuticals, Ltd	Methods of reducing inflammation and mucus hypersecretion
US7544772B2 (en)	2001-06-26	2009-06-09	Biomarck Pharmaceuticals, Ltd.	Methods for regulating inflammatory mediators and peptides useful therein
US6245320B1 (en)	1999-09-01	2001-06-12	University Of Maryland	Inhibition of mucin release from airway goblet cells by polycationic peptides
AU7709300A (en)	1999-09-24	2001-04-24	Linden Technologies, Inc.	Drug discovery using gene expression profiling
DK1104758T3 (da)	1999-12-03	2003-10-20	Pfizer Prod Inc	Acetylenderivativer som anti-inflammatoriske/analgesiske lægemidler
US7919469B2 (en)	2000-02-24	2011-04-05	North Carolina State University	Methods and compositions for altering mucus secretion
US7265088B1 (en)	2000-02-24	2007-09-04	North Carolina State University	Method and compositions for altering mucus secretion
WO2003000027A2 (en) *	2001-06-26	2003-01-03	North Carolina State University	Blocking peptide for inflammatory cell secretion
JP2004049133A (ja)	2002-07-22	2004-02-19	Kumamoto Technology & Industry Foundation	Ｎ−ミリストイルトランスフェラーゼ活性の測定方法
WO2006023312A2 (en)	2004-08-20	2006-03-02	Carl Deirmengian	Diagnostic assay for source of inflammation
US7408030B2 (en)	2005-01-13	2008-08-05	North Carolina State University	Purification of immunoglobulins using affinity chromatography and peptide ligands
WO2006078899A2 (en) *	2005-01-20	2006-07-27	Biomarck Pharmaceuticals, Ltd.	Mucin hypersecretion inhibitors based on the structure of mans and methods of use
SG10201500418QA (en)	2006-07-26	2015-03-30	Biomarck Pharmaceuticals Ltd	Methods for attenuating release of inflammatory mediators and peptides useful therein

2007
- 2007-07-26 SG SG10201500418QA patent/SG10201500418QA/en unknown
- 2007-07-26 WO PCT/US2007/074514 patent/WO2008014414A2/en not_active Ceased
- 2007-07-26 EP EP14151431.5A patent/EP2722052B1/en active Active
- 2007-07-26 JP JP2009522007A patent/JP5378998B2/ja not_active Expired - Fee Related
- 2007-07-26 BR BRPI0714953-0A2A patent/BRPI0714953A2/pt not_active Application Discontinuation
- 2007-07-26 DK DK07840538.8T patent/DK2053915T3/da active
- 2007-07-26 SI SI200731481T patent/SI2053915T1/sl unknown
- 2007-07-26 PL PL14151431T patent/PL2722052T3/pl unknown
- 2007-07-26 PT PT78405388T patent/PT2053915E/pt unknown
- 2007-07-26 ES ES14151431T patent/ES2725599T3/es active Active
- 2007-07-26 CN CN201410224653.8A patent/CN103990111B/zh not_active Expired - Fee Related
- 2007-07-26 SG SG2011053303A patent/SG173411A1/en unknown
- 2007-07-26 CN CN200780035710.6A patent/CN101516190B/zh not_active Expired - Fee Related
- 2007-07-26 CA CA2658949A patent/CA2658949C/en active Active
- 2007-07-26 ZA ZA200900550A patent/ZA200900550B/xx unknown
- 2007-07-26 CA CA2842219A patent/CA2842219C/en active Active
- 2007-07-26 HR HRP20140587TT patent/HRP20140587T1/hr unknown
- 2007-07-26 EP EP07840538.8A patent/EP2053915B1/en active Active
- 2007-07-26 AU AU2007279193A patent/AU2007279193B2/en not_active Ceased
- 2007-07-26 PL PL07840538T patent/PL2053915T3/pl unknown
- 2007-07-26 KR KR1020097004065A patent/KR101599894B1/ko not_active Expired - Fee Related
- 2007-07-26 ES ES07840538.8T patent/ES2488092T3/es active Active
- 2007-07-26 RU RU2009106673/04A patent/RU2423376C2/ru active
- 2007-07-26 MX MX2009000975A patent/MX2009000975A/es active IP Right Grant
- 2007-07-26 DK DK14151431.5T patent/DK2722052T3/en active
2009
- 2009-01-20 NO NO20090304A patent/NO20090304L/no not_active Application Discontinuation
- 2009-01-22 IL IL196667A patent/IL196667A/en active IP Right Grant
- 2009-01-26 US US12/359,892 patent/US8999915B2/en active Active
2013
- 2013-07-11 JP JP2013145459A patent/JP5819889B2/ja not_active Expired - Fee Related
2015
- 2015-03-04 US US14/638,208 patent/US9827287B2/en not_active Expired - Fee Related
2017
- 2017-10-20 US US15/789,442 patent/US20180036367A1/en not_active Abandoned
2018
- 2018-12-28 US US16/235,880 patent/US20200138898A1/en not_active Abandoned
2021
- 2021-05-04 US US17/307,471 patent/US20210260154A1/en not_active Abandoned
2023
- 2023-04-05 US US18/296,275 patent/US20230293629A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US9827287B2 (en)	2017-11-28
WO2008014414A2 (en)	2008-01-31
EP2053915B1 (en)	2014-06-11
JP5378998B2 (ja)	2013-12-25
IL196667A0 (en)	2011-08-01
CN103990111A (zh)	2014-08-20
MX2009000975A (es)	2009-04-07
ES2488092T3 (es)	2014-08-26
JP2009544737A (ja)	2009-12-17
US8999915B2 (en)	2015-04-07
US20200138898A1 (en)	2020-05-07
SI2053915T1 (sl)	2014-10-30
EP2722052A1 (en)	2014-04-23
IL196667A (en)	2017-04-30
JP5819889B2 (ja)	2015-11-24
JP2013241428A (ja)	2013-12-05
RU2423376C2 (ru)	2011-07-10
EP2722052B1 (en)	2019-03-20
KR101599894B1 (ko)	2016-03-04
WO2008014414A3 (en)	2008-09-25
ES2725599T3 (es)	2019-09-25
HK1201190A1 (en)	2015-08-28
HK1125793A1 (en)	2009-08-21
DK2053915T3 (da)	2014-06-30
SG173411A1 (en)	2011-08-29
CA2842219C (en)	2017-07-11
US20230293629A1 (en)	2023-09-21
RU2009106673A (ru)	2010-09-10
CN101516190B (zh)	2014-06-11
EP2053915A4 (en)	2011-06-08
CN103990111B (zh)	2016-08-31
DK2722052T3 (en)	2019-04-29
AU2007279193B2 (en)	2011-12-01
BRPI0714953A2 (pt)	2013-07-16
HRP20140587T1 (hr)	2014-11-21
KR20090037487A (ko)	2009-04-15
CA2658949C (en)	2014-04-22
US20210260154A1 (en)	2021-08-26
SG10201500418QA (en)	2015-03-30
US20180036367A1 (en)	2018-02-08
CA2658949A1 (en)	2008-01-31
US20160030509A1 (en)	2016-02-04
US20090203620A1 (en)	2009-08-13
PT2053915E (pt)	2014-08-25
EP2053915A2 (en)	2009-05-06
CA2842219A1 (en)	2008-01-31
NO20090304L (no)	2009-04-21
PL2053915T3 (pl)	2014-12-31
AU2007279193A1 (en)	2008-01-31
CN101516190A (zh)	2009-08-26
ZA200900550B (en)	2010-03-31

Publication	Publication Date	Title
SG10201500418QA (en)	2015-03-30	Methods for attenuating release of inflammatory mediators and peptides useful therein
SG10201405436WA (en)	2014-10-30	Methods for regulating inflammatory mediators and peptides useful therein
EP1899480A4 (en)	2009-04-22	COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY CONDITIONS
PT2101766T (pt)	2016-12-28	Composições e métodos de utilização de (r)-pramipexole
SI2079760T1 (sl)	2016-11-30	Sestavki in metode za zdravljenje okužb
IL196956A0 (en)	2009-11-18	Aza-benzofuranyl compounds and methods of use
EP2355717A4 (en)	2012-05-02	METHOD AND SYSTEMS FOR DETECTING AND REMOVING HARN STONES FROM BODY HOLLOWS
EP2073844A4 (en)	2011-06-01	METHOD FOR TREATING SYSTEMIC LUPUS ERYTHEMATODES
IL195619A0 (en)	2009-09-01	Compositions and methods for joininig non-conjoined iumens
IL197060A0 (en)	2009-11-18	Aza-benzothiophenyl compounds and methods of use
GB201108374D0 (en)	2011-06-29	Compositions and methods for the treatment of altered synuclein function
IL197781A0 (en)	2009-12-24	Lyophilization methods and apparatuses
EP2014437A4 (en)	2010-06-30	METHOD FOR MOLDING A STRUCTURAL ELEMENT IN COMPOSITE MATERIAL AND STRUCTURAL ELEMENT IN COMPOSITE MATERIAL
ZA200905273B (en)	2010-04-28	Compositions and methods of use of phorbol esters
ZA200808017B (en)	2009-11-25	Tetrahydropyridothienopyrimidine compounds and methods of use thereof
PL2069467T3 (pl)	2015-02-27	Kompozycje wydzielające i sposoby stosowania
PL2101766T3 (pl)	2017-04-28	Kompozycje i sposoby stosowania (R)-pramipeksolu
IL232011A0 (en)	2014-05-28	Antibodies to 7egfl and methods of using them
IL208809A0 (en)	2011-01-31	Saccharide structures and methods of making and using such structures
ZA200810831B (en)	2009-10-28	Formulations with feruloyl glycerides and methods of preparation
ZA200900896B (en)	2010-06-30	Aza-benzofuranyl compounds and methods of use
ZA200901009B (en)	2010-05-26	Aza-benzothiophenyl compounds and methods of use
ZA200807225B (en)	2009-11-25	Antibodies to EGFL7 and methods for their use
IL192552A0 (en)	2009-09-22	Dnt-succinate and methods of preparation thereof
HK1123730A (en)	2009-06-26	Methods for regulating inflammatory mediators and peptides useful therein